Effectiveness and Cost-effectiveness of a Pre-emptive Genotyping Strategy in Patients Receiving Tacrolimus

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 114 participants.

Also called NCT06701825

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 114 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06701825
  • EU CT 2024-516596-32-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Spain (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06701825. Randomized; single masking; primary purpose treatment. Start 2025-06-02 (actual); primary completion 2026-10-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effectiveness and Cost-effectiveness of a Pre-emptive Genotyping Strategy in Patients Receiving Tacrolimus
Acronym
TRANSPGx
Condition
Kidney Disease, Chronic
Condition
Transplant Recipient (Kidney)
Condition
Immunosuppression
Intervention (Drug)
Tacrolimus
Intervention (Drug)
Tacrolimus
Lead sponsor
Instituto de Investigación Hospital Universitario La Paz (class: other)
Collaborator
Instituto de Salud Carlos III (class: other government)

Record details

Record id
cardio:ct-nct06701825
Content hash
c49cfa8ff5072bbda8696fc175d16e9530e65ff21fb286d9adcabd54fc65329b